Q-omics provides the consensus-scored LRRC9 profile across patient tissues and cancer cell-line models. LRRC9 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LRRC9 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, LRRC9 RNA expression shows 18,588 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, and THYM as cancer lineages where LRRC9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LRRC9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LRRC9 survival associations across molecular data types. LRRC9 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LRRC9 RNA expression–survival associations across cancer types. High LRRC9 expression shows unfavorable associations in HNSC, LGG, UCEC and ACC, but favorable associations in UCS and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for LRRC9 RNA expression.
This table summarizes LRRC9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LRRC9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LRRC9 shows lower tumor expression in KIRP and THCA and higher tumor expression in HNSC, KICH, COAD and LUSC. The HNSC box plot shows higher LRRC9 RNA expression in tumor versus normal tissue (log2 FC = +0.199, t-test p < 0.001).
This table shows molecular features associated with LRRC9 in patient tissues and cancer cell lines. In patient samples, LRRC9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LRRC9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
